Pharvaris N.V.
(PHVS)
undefined
undefined%
At close: undefined
18.40
-0.59%
After-hours Dec 13, 2024, 04:00 PM EST
Company Description
Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases.
The company develops PHA121, a small molecule bradykinin B2-receptor antagonist that is in Phase II clinical trial for the treatment of hereditary angioedema (HAE).
It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks and is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients and is under Phase 1 clinical trial.
It operates in the Netherlands, Switzerland, and the United States.
The company was incorporated in 2015 and is based in Leiden, the Netherlands.
Pharvaris N.V.
| Country | NL |
| IPO Date | Feb 5, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 83 |
| CEO | Berndt Axel Edvard Modig CPA, M.B.A. |
Contact Details
Address: J.H. Oortweg 21 Leiden, NL | |
| Website | https://pharvaris.com |
Stock Details
| Ticker Symbol | PHVS |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001830487 |
| CUSIP Number | N69605108 |
| ISIN Number | NL00150005Y4 |
| Employer ID | 00-0000000 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Berndt Axel Edvard Modig CPA, M.B.A. | Co-Founder, Chief Executive Officer & Executive Director |
| David W. Nassif J.D. | Chief Financial Officer & Corporate Secretary |
| Anna Nijdam M.Sc., R.A. | Head of Strategic Finance & Principal Accounting Officer |
| Annick Deschoolmeester | Chief Human Resources Officer |
| Dr. Anne A. Lesage Ph.D. | Chief Early Development Officer |
| Dr. Peng Lu M.D., Ph.D. | Chief Medical Officer |
| Dr. Stefan Abele Ph.D. | Chief Technology Operations Officer |
| Maryann Cimino | Director of Corporate Relations |
| Wim Souverijns Ph.D. | Chief Commercial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 13, 2024 | 6-K | Filing |
| Sep 25, 2024 | 6-K | Filing |
| Sep 23, 2024 | 6-K | Filing |
| Sep 05, 2024 | 6-K | Filing |
| Aug 14, 2024 | 6-K | Filing |
| Jun 28, 2024 | 6-K | Filing |
| Jun 11, 2024 | 6-K | Filing |
| Jun 04, 2024 | 6-K | Filing |
| May 08, 2024 | 6-K | Filing |
| Apr 12, 2024 | F-3ASR | Filing |